{"name":"Synthekine","slug":"synthekine","ticker":"","exchange":"","domain":"synthekine.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"STK-009","genericName":"STK-009","slug":"stk-009","indication":"Other","status":"phase_1"},{"name":"STK-012","genericName":"STK-012","slug":"stk-012","indication":"Other","status":"phase_1"},{"name":"SYNCAR-001","genericName":"SYNCAR-001","slug":"syncar-001","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"STK-009","genericName":"STK-009","slug":"stk-009","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"STK-012","genericName":"STK-012","slug":"stk-012","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SYNCAR-001","genericName":"SYNCAR-001","slug":"syncar-001","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi4AJBVV95cUxQRU1KZVNLSF9GUmwxdDluVGNiMU80RnFKTGFuekhoNWV4dG55OGc4SVp4czZpVGl1Ym5XSTk3cW10a0pKVGRFdlVNUUFCelJ0WTk2dzZkQzg1dmN2amdSNHFiQm9nTkRBeTVxTEx4SW5mbkNGTkxCeGc1SnhNY3UwUmNlYWJOMkhIWU50LXBQZXY1aW5oMTh1bUFIN0ZEVjEwTDNIY3EzMG5meXhCTEExaGduNV93YklKODJCRWJVcVdrd2EzWjZQRW9TODYtUnpwZXVYWG5vbmI2Rm56RzM3S0pCWldVSWtjc2hWYmxIMWhrZXNCSzQ4dG9kMDdtZ0FSc2lJTGhEaE14QTVxUVVJUEpzZnlfNTl4WUcwaHlKQVZpdmhLWDNlaEFYcnRaRGZ6VldoaGR5Y0RRN0tPR2h3LUhlOGlueFJpUDRDTEp4NjhzWV9tMERoc1diTzdoZmpK?oc=5","date":"2026-03-17","type":"trial","source":"Business Wire","summary":"Synthekine Announces AACR 2026 Oral Presentation of Updated Phase 1a/1b Clinical and Translational Data for STK‑012 in First‑Line Nonsquamous NSCLC with Features of Immunotherapy Resistance - Business","headline":"Synthekine Announces AACR 2026 Oral Presentation of Updated Phase 1a/1b Clinical and Translational Data for STK‑012 in F","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-26","type":"trial","source":"Business Wire","summary":"Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1","headline":"Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembroli","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxQaktuZXdhYm5TRERzZl9WTjBuSjNWM0NvLWFyazI0WUoybUF3Wlg2YnJqSUJqMmlFdjNMemhPWWZkbWVYMi1lVW1rR1N0WTdkTGMtTGZBMkFRLVVBX0RuNnctRnI3ODdMUFZOTk5pQW5YV01SRXpBT0lHeUctcVMwWE1TMTZpTzBSc3ZxUHBkdHFWaFlZMzl5N01GNU5za0h2a0xqeDFZWHBnSGZDenFKTUVfZFpqLTNjVjBCSHpmbURtQTJXcFhkQTZQa1BHTVFINVlBSVhQZ1FnZ3F4a3FhV09URUdldDBvYlN4bXJR?oc=5","date":"2026-02-23","type":"pipeline","source":"BioSpace","summary":"Synthekine Appoints Biotechnology and Pharmaceutical Industry Veteran John A. Orwin as Chair of its Board of Directors - BioSpace","headline":"Synthekine Appoints Biotechnology and Pharmaceutical Industry Veteran John A. Orwin as Chair of its Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAJBVV95cUxON3haaElHU09WM2UxVFAtWGQyRUtONkJKSURwc1E0bWVjVnRTVTRTVklWSFBiZURWLWgtQWhEcGFBNmZLM0FhTFFZeE5tWE90dnRVRzk2bVlVVFEzS3dtX3c5T3Y3allKd1E2UEhUbzJGdnk0SlR4Z2hsTkxHTy1XNTljamJJcnJ2WG5YVUd2RS1pWlE4aHp0WFR2TGU1WGcxa3Fabk0walIxdGZCXzg3amhpTkpJSm12ajR5akpkTVpuc1RaSUZKek1yZEc1WVFGWVkwSnZBX1Q2T0EtUmlaREM4eVl4T3RoRE1iZmpkTTk0VUM2NXRhdkdxc3ZNOEJMTVc3Zk5HcUp0bzdESU42OFN0cmQ1ZDFYX0JzdVZBV0gtZjY0cDQzUl9sQ01fSllFcjhhRA?oc=5","date":"2025-07-10","type":"trial","source":"GlobeNewswire","summary":"Interleukin-2 Inhibitors Clinical Trial Pipeline - GlobeNewswire","headline":"Interleukin-2 Inhibitors Clinical Trial Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxQLUdGNExlVk1Yb25WMVhZWUlQUzgteV93WGRaSHU4WWZzMDFUYURLQXV5dFdHM3JTcERzSVQ5eUlLOFRSTXFsak8xdFJ4RmpHblB6YXJWY0tXMnhrQWluUk5OTkRqWTZvWHB0UkUyMndISW9XSS1tNDhnTDVnZmVxZm1lWUVLM3VVb2Y0dzJ2ZDExNWlhNk84RERxRkJSY2RubzhfSHZPZ3JpQ1NhSWV3ODltTlc3TF9ZWlV4LXFNWV9EdFlOT1RQNnFGeVotT3l3LWhmd2Z1Y19DcmtfQzJqdDlSaFlsZWJhWmlPMVluVkIzTmRPcTQxcDZ1UkhicGVfQUFqZ3QtZHVfTEQ1RXB4UmFkVkRmeXduUU1XQzM2YU5Jb002cnNpb01B?oc=5","date":"2024-11-28","type":"trial","source":"PR Newswire","summary":"Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire","headline":"Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therape","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOYWpwbEpiZ3dONlFOcUxPdUZNclU4Mi1mQ2xhclg4cndHdjZCenRyZi1sbkN3TlUySVNMVDNZdFNKOFZibm1jamJveVk3cjNWQVFMZEJROWtQeUY5WVdsOWUyZjFfVzctRnZxOHdka3hJbjA1c3o4VHN5UTV2djBENkltZFNhRFRoejlWVlhJOXNLYnMxWUhMZnlqajVMREE?oc=5","date":"2024-04-10","type":"pipeline","source":"Fierce Biotech","summary":"AACR: Synthekine hopes new IL-2 will be the high-alpha in a beta class - Fierce Biotech","headline":"AACR: Synthekine hopes new IL-2 will be the high-alpha in a beta class","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNSEZqaTRrZmhCTlNpeU1PUWsyT1VoYlhvT3pSWFQ3NUlwNXdxTmRXMTlST2Y4eTVucUR5UU0tZEFqYlctX2VLOWlzV1pPZVRydVJxNGktaHB6eFNrR1A0YTg1T0NMZVdpZTZjdnJmMVFHRnpubkNDNW52ZHVqUjltdWtaczFiS2hRdFNGekU5VTN6dG5DV0hEbmhIV2poa2VmM1Zqd2prQ3g4YVNTYUE?oc=5","date":"2024-01-30","type":"deal","source":"Pharmaceutical Technology","summary":"Sanofi partners with Synthekine to develop IL-10 therapeutics - Pharmaceutical Technology","headline":"Sanofi partners with Synthekine to develop IL-10 therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQN3ZING02QWdDdjhrMHlQQ3dPUFMtNDlzb3o0enBfU3lremlDTmVjUjdCRjA4eEM0WDN4MzAtVHBlSm5mTDlVelBua21FUTV4WkZrbE1zRVBmamFLbThjSHpIejhKTF8zY0l3dVNYbmpxYjVEWlJmdk54OEFCSS1EWjhrX3o3cDR4aEFfa1Vn?oc=5","date":"2024-01-29","type":"pipeline","source":"MedCity News","summary":"Sanofi Tries Again With Cytokines, Inking R&D Alliance With Startup Synthekine - MedCity News","headline":"Sanofi Tries Again With Cytokines, Inking R&D Alliance With Startup Synthekine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQVnJucGtFaHg1OUVZcWdNVnprTDNQdFo5U3I1MVZSZkpjY1RxZDRYYmtwMXI0cGd3Nklnc1Uzay00dzNhaEZsYlJLR3JDajc5X1EzNWRkSHNSWGIycTRCeHFqNHhacnROYm1sdDh0TTRPWENPVlhMT2xoUTNZbElGa29qNkFZc3loeFdaclBTNlpqZ3NiWFAxYTZOUkNfbW5HNGczaGU2b25uM3YxMzlsS0VR?oc=5","date":"2024-01-29","type":"deal","source":"Genetic Engineering and Biotechnology News","summary":"Dupixent Redux? Synthekine, Sanofi Partner on Cytokine Therapies - Genetic Engineering and Biotechnology News","headline":"Dupixent Redux? Synthekine, Sanofi Partner on Cytokine Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNMW1RUFd1LUtocE1abGZBRUpOcTZlNDVMcWVnTVRGVUlMNkJWcGxyT3JpUTZSLTBRVFRzS2w5eU5TTjE3VWp3elVjVEhVd0xqRWdpWWhfZkZnMjQ4aEF6eXdxcWo5dS1BcmF6UWE3NzhmZ2huNFlxaGJVYW4xdE5FLWY4eFk?oc=5","date":"2022-11-14","type":"deal","source":"pharmaphorum","summary":"Merck teams up with Synthekine in $525m cytokine partnership - pharmaphorum","headline":"Merck teams up with Synthekine in $525m cytokine partnership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPQWpYTlNZMHhTcGF0bU05UHUwT3NIWW9zMng4eldWTjV6d0dlQ255c2dnWE9TSFcyRW5CSjVSWlNqZXFmUXh4Qk1oUy1tT3U5WHU4dGRkc0lESG1hTTZ1Z0NiQmVJVjVBRE5ZeHUzUVFMaHZZM1VsbzZqZ0RVUnRNMWJWRXZHMkpHOFc4OGZhdE1FNXJsT3Y4SlotX2R5UzZweGZrYjlDRGRNWjFaNVRPczV5bGhPdw?oc=5","date":"2022-09-30","type":"pipeline","source":"Fierce Pharma","summary":"'The Top Line': The Fierce 15, Fierce Biotech Summit highlights - Fierce Pharma","headline":"'The Top Line': The Fierce 15, Fierce Biotech Summit highlights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNd3R3di11V3Y0SjE3TEpTWlZuYkpNV25xTzRvR3F2eGlzbEYyb2E3ZHVFWVpVUFpyUTJjWnJDSXoxSGl6Y25YdVB1cV9xWW9uelVZQ0NwOWJUYXFBN1JCbUxDRE1HbG9IbUJkeHpJaGxPRWwwUkxfeWptSnpfV1RTS24wSTRHekNrZVpmX1RCTkJ1dExLMVhtR0NHeUFYUWVIX2FsM09tdTNPanBGMHBGdVFZT2dNVkE?oc=5","date":"2021-06-10","type":"trial","source":"Fierce Biotech","summary":"Synthekine scores major $108M B round to secure set of trials in 12 months - Fierce Biotech","headline":"Synthekine scores major $108M B round to secure set of trials in 12 months","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}